PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 2001Journal of Pharmacy and Pharmacology730 citationsOpen Access

St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties

View Full Paper
JBJoanne BarnesLALinda A. AndersonJPJ. David Phillipson

Key Points

Key points are not available for this paper at this time.

Abstract

The chemical composition of St. John's wort has been well-studied. Documented pharmacological activities, including antidepressant, antiviral, and antibacterial effects, provide supporting evidence for several of the traditional uses stated for St John's wort. Many pharmacological activities appear to be attributable to hypericin and to the flavonoid constituents; hypericin is also reported to be responsible for the photosensitive reactions that have been documented for St. John's wort. With regard to the antidepressant effects of St John's wort, hyperforin, rather than hypericin as originally thought, has emerged as one of the major constituents responsible for antidepressant activity. Further research is required to determine which other constituents contribute to the antidepressant effect. Evidence from randomised controlled trials has confirmed the efficacy of St John's wort extracts over placebo in the treatment of mild-to-moderately severe depression. Other randomised controlled studies have provided some evidence that St John's wort extracts are as effective as some standard antidepressants in mild-to-moderate depression. There is still a need for further trials to assess the efficacy of St John's wort extracts, compared with that of standard antidepressants, particularly newer antidepressant agents, such as the selective serotonin reuptake inhibitors (recent comparative studies with fluoxetine and sertraline have been conducted). Also, there is a need for further studies in well-defined groups of patients, in different types of depression, and conducted over longer periods in order to determine long-term safety. St John's wort does appear to have a more favourable short-term safety profile than do standard antidepressants, a factor that is likely to be important in patients continuing to take medication. Concerns have been raised over interactions between St John's wort and certain prescribed medicines (including warfarin, ciclosporin, theophylline, digoxin, HIV protease inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, triptans, oral contraceptives); advice is that patients taking these medicines should stop taking St John's wort, generally after seeking professional advice as dose adjustment of conventional treatment may be necessary.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Barnes et al. (2001) studied this question.

synapsesocial.com/papers/69d8be698df8c70967ae2b3ehttps://doi.org/10.1211/0022357011775910
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of Monoamine Oxidase by Hypercin1984 · 208 citations
  2. 2Pharmacodynamic Effects of two Different Hypericum Extracts in Healthy Volunteers Measured by Quantitative EEG1998 · 50 citations
  3. 3Hypericin as a Non-Antioxidant Inhibitor of NF-κB1999 · 63 citations
  4. 4booming U.S. Botanical market: a new overview1998 · 148 citations
  5. 5Alcohol and Central Serotonin Metabolism in Man1979 · 364 citations